SPECIFICATION
| Product name | Orlistat Powder |
Appearance | White powder |
Content of Active ingredient | 99% |
Odor | Characteristic |
Taste | Characteristic |
Loss on drying | NMT1.0% |
Sulphated Ash | NMT1.0% |
Heavy Metals | NMT 10ppm |
Residual Solvents | Eur.Pharm. |
| Total Plate Count | NMT 1000cfu/g |
| Yeast & Moulds | NMT 100cfu/g |
E.Coli. | Negative |
Salmonella | Negative |
Enterobacteria | Negative |
Staphylococcus aureus | Negative |
Conclusion | Conform with specification |
Packing | 25 kg/paper drum |
| Storage | Store in sealed containers at cool & dry place. Protect from light, moisture and pest infestation. |
Shelf life
| Two years if sealed and store away from direct sun light. |
USAGE
| Product name | Orlistat |
| Usage | Orlistat
is used for the treatment of obesity.The amount of weight loss achieved
with orlistat varies. In one-year clinical trials, between 35.5% and
54.8% of subjects achieved a 5% or greater decrease
in body mass, although not all of this mass was necessarily fat.
Between 16.4% and 24.8% achieved at least a 10% decrease in body
mass. After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively). |
Description：
Orlistat Powder is a therapeutic drug for obesity that does not act on the central nervous system. It acts only on the gastrointestinal tract, inhibits the hydrolysis of triglyceride into free fatty acids and monoacylglycerides by inhibiting the lipase of the gastrointestinal tract, and reduces the absorption of fat (triacylglycerol) in the diet by the intestinal mucosa, and promotes the elimination of fat in vitro. Lipase is an enzyme necessary for the gastrointestinal tract to break down fat. This product can bind to the serine residue of stomach and pancreatic lipase, and inactivate lipase, so that it can not break down fat in food into free fatty acid and inhibit fat. Utilization and absorption, in addition, this product can reduce the risk factors associated with obesity.
Application：
Obesity and overweight who have undergone moderate dietary control and exercise, including long-term treatment of patients who have already developed obesity-related risk factors (diabetes, hypertension, dyslipidemia, etc.).